Vanda Pharmaceuticals Inc. (VNDA) · Nov 20, 2026 · Material agreement
HETLIOZ LQ license — MSN launch generally barred until Q1 2040
Vanda’s settlement ends the MSN HETLIOZ LQ patent fight and delays a generic launch to 2040, but brings no disclosed near-term cash.
Vanda is a commercial-stage biopharma defending HETLIOZ LQ while expanding a broader product portfolio; HETLIOZ generated $21.7 million of U.S. net sales in the third quarter of 2026, and the company’s latest public filing still described the MSN litigation as pending.
The settlement removes the immediate trial risk and establishes a long runway for HETLIOZ LQ. Vanda entered the agreement with MSN on November 16, 2026, resolving the Delaware patent case. 〔0〕 Under the deal, Vanda grants MSN a royalty-free license, but the ordinary license date is in the first quarter of 2040, materially extending the expected period before this specific generic can launch. 〔1〕
This is better than carrying the case into trial, but it is not a cash-generating transaction. MSN acknowledges that the asserted patents are valid and enforceable for its ANDA product and agrees not to challenge them, while Vanda releases related claims and the parties seek dismissal and a permanent injunction. 〔2〕 The filing discloses no upfront payment, damages recovery, or royalty stream; the value is primarily preserving commercial protection and reducing litigation uncertainty.
The protection is strong but not absolute. MSN can enter earlier if the patents fall, another generic launches and Vanda does not stop it, Vanda launches an authorized or licensed generic, or HETLIOZ LQ is withdrawn for non-safety or non-efficacy reasons and a shortage is declared. 〔3〕 Those carve-outs keep the settlement from rewriting the entire HETLIOZ outlook, but the normal-case outcome is clearly more favorable than an unresolved patent trial.
Bottom line: This is a modestly positive business development: Vanda converts a live patent dispute into a long-dated generic timetable and removes MSN as an immediate threat, without adding near-term revenue or cash.
FTC/DOJ review and consent judgment
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!